Clinical Trial Update: Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for fondaparinux sodium (GSK576428) in total hip replacement; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thrombosis

Drugs mentioned

• Fondaparinux sodium (Fondaparinux sodium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Thrombosis, Venous | Phase 3 | Status: COMPLETED | Results posted: 2017-12-21